Relationship between oral administration of garenoxacin and QT interval

Japanese Journal of Chemotherapy

Volumn 55, Issue SUPPL. 1, 2007, Pages 214-221

  Murakawa, Yuji ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Des fluoro(6) quinolone; Electrocardiogram; Garenoxacin; QT

Indexed keywords

GARENOXACIN; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE COMPARISON; FEMALE; FOOD; FOOD DRUG INTERACTION; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; PHASE 3 CLINICAL TRIAL; QT PROLONGATION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 35349028479     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. The ICH Steering Committee. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-anti-arrhythmic drugs (E 14). The international conference on harmonization of technical requirements for registration of pharmaceuticals for human use (ICH). The Guideline was recommended for adoption at Step 4 of the ICH process in May 2005
2. Committee for Proprietary Medicinal Products (CPMP). Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products CPMP 986/96, London, December 17, 1997
3. Japanese source.
4. Demolis JL, Kubitza D, Tenneze L, Funck-Brentano C: Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000; 68: 658-66
5. Krishna G, Gajjar D, Swan S, Marbury T, Grasela D M, Wang Z: Garenoxacin pharmacokinetics in subjects with renal impairment. Curr Med Res Opin 2007; 23: 649-57